XW-10508 is under clinical development by XWPharma and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XW-10508’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XW-10508 is under development for the treatment of major depressive disorder, treatment resistant depression and chronic pain. It is administered through oral route. The drug candidate acts by targeting both N-methyl-D-aspartate receptor (NMDA) and glutamate ionotropic receptor (AMPA).
XWPharma, formerly XW Laboratories, is a biopharmaceutical company that discovers and develops treatments for neurodegenerative diseases. It is investigating XW10172, a GABAB (G-protein coupled receptors for gamma-aminobutyric acid) agonist NCE (new chemical entity) targeting sleep disorders in Parkinson’s disease; excessive daytime sleepiness (EDS) and cataplexy in narcolepsy. The company is also evaluating XW10508, a glutamatergic NMDA (N-methyl-D-aspartate) and AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) activator NCE to treat major depressive disorder and chronic pain. It has operations in California, the US; and Taipei, Taiwan. XWPharma is headquartered in Wuhan, Hubei, China.
For a complete picture of XW-10508’s drug-specific PTSR and LoA scores, buy the report here.